查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1539344

感染疾病诊断市场:全球产业分析，规模，占有率，成长，趋势，预测，2024-2033年

Infectious Diseases Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033
出版日期: | 出版商: Persistence Market Research | 英文 241 Pages | 商品交期: 2-5个工作天内

价格
简介目录

Persistence Market Research最近发布了一份关于全球传染病诊断市场的深入研究报告，提供了对市场推动因素、趋势、机会和课题等市场动态的详细见解。本报告旨在提供对市场结构和未来前景的全面了解，特别是医疗保健和诊断领域的利害关係人。

主要洞察

  • 全球市场收入（2022 年）：351 亿美元
  • 预计市场价值（2033 年）：551 亿美元
  • 全球市场成长率（2022-2033 年复合年增长率）：4.2%

全球传染病诊断市场 - 报告范围：

新兴市场包括用于识别传染病的诊断测试套件和系统的开发、生产和分销。该市场涵盖多种疾病，包括呼吸道感染、性传染感染（STI）以及其他需要及时准确诊断才能有效治疗的传染病。

推动市场成长的因素：

传染病发生率增加

全球传染病流行持续加剧，增加了对有效诊断解决方案的需求。呼吸道疾病和性传染病的发生率尤其高，需要加强诊断检测来管理和控制这些疾病。例如，根据世界银行的数据，2020年将有3,770万人感染爱滋病毒，其中一半是妇女和女孩。对此类感染的准确诊断和及时治疗的需求预计将推动对传染病诊断的需求。

越来越多地关注实证医学 (EBM)

实证医学 (EBM) 在医疗保健环境中变得越来越重要，因为它可以帮助临床医生实现更高品质的照护、提高病患满意度并降低成本。 EBM不仅利用证据来制定治疗方案，还鼓励患者和临床医生之间的对话，让患者参与决策。对实证诊断的重视正在推动对诊断试剂盒的需求，因为临床医生依靠准确的诊断结果来指导治疗决策。

对快速诊断测试 (RDT) 的需求不断增加

随着越来越多的患者患有需要快速且准确诊断的传染病，对快速诊断测试 (RDT) 的需求不断增加。例如，世界卫生组织 (WHO) 报告称，2010 年至 2020 年间，全球销售了 31 亿粒治疗疟疾的 RDT，其中 81% 销往撒哈拉以南非洲国家。对可靠且低成本的诊断试剂盒的需求不断增加，为市场成长创造了重大机会。

市场课题

诊断测试套件成本高

虽然传染病诊断市场正在扩大，但可用诊断测试套件的高成本仍然是一个主要课题。需要具有高特异性和敏感性的经济高效的检测试剂盒来使诊断更容易，特别是在资源匮乏的环境中。目前诊断工具的高成本限制了其广泛使用，特别是在发展中国家。

缺乏有效的诊断测试套件

许多传染病的高效诊断检测试剂盒供不应求。开发负担得起且可靠的检测试剂盒对于满足高收入和低收入地区不断增长的诊断需求至关重要。越来越多的公司正在专注于研发高精度和灵敏的诊断试剂盒，这有望在市场上创造新的商机。

成长机会：

聚焦传染病预防

各国都将重点放在传染病预防上，以减少医疗支出。例如，印度健康基金会与印度政府首席科学顾问办公室合作，呼吁进行创新，以解决影响传染病控制、治疗和治癒的紧迫问题。随着政府和医疗机构寻求加强其诊断能力，此类措施为传染病诊断试剂盒供应商提供了重大的成长机会。

扩大研发

扩大旨在製造高精度和灵敏诊断试剂盒的研发预计将为从事传染病诊断的公司创造新的业务前景。专注于技术创新和开发更有效的诊断解决方案预计将在未来几年推动市场成长。

本报告涵盖的主要问题

  • 推动全球传染病诊断市场成长的关键因素有哪些？
  • 哪个消费族群正在推动传染病诊断解决方案的采用？
  • 技术进步如何影响竞争格局？
  • 谁是全球传染病诊断市场的主要参与者？
  • 全球传染病诊断市场的新趋势和未来前景是什么？

目录

第1章 摘要整理

第2章 市场概要

  • 市场范围/分类
  • 市场定义/范围/限制
  • 包含和排除

第3章 主要市场趋势

  • 影响市场的主要趋势
  • 产品革新/开发趋势

第4章 重要成功要素

  • 生产引进分析
  • 法规情势
  • 偿付的形势
  • 供应链分析
  • PESTEL分析
  • 波特分析

第5章 市场背景

  • 宏观经济要素
  • 预测要素- 相关性及影响
  • 市场动态

第6章 COVID-19危机分析

  • COVID-19及影响分析
  • 2024年的市场情势

第7章 全球感染疾病诊断市场需求(金额)分析

  • 市场(金额)分析，2019～2023年
  • 市场(金额)预测，2024～2033年
    • 前一年同期比较成长趋势分析
    • 绝对的商机

第8章 各产品:全球感染疾病诊断市场分析

  • 简介/主要调查结果
  • 市场(金额)分析，2019～2023年
  • 市场(金额)预测，2024～2033年
  • 设备
    • 生物晶片
    • 微流体为基础的POCT
    • DNA微阵列
    • 质谱分析
    • 即时聚合酵素链锁反应(qPCR)
    • 萤光原位杂合反应(FISH)
    • 定序
    • 毛细管电泳法
    • 次世代定序
  • 套件和试剂
    • 套件
    • 一次抗体
    • 二次抗体
    • 基材
    • 缓衝
  • 消耗品
  • 各产品市场魅力分析

第9章 各检验类型:全球感染疾病诊断市场分析

  • 简介/主要调查结果
  • 市场(金额)分析，2019～2023年
  • 市场(金额)分析与预测，2024～2033年
    • 筛检检验
    • 诊断检验
  • 各检验类型的市场魅力分析

第10章 各应用领域:全球感染疾病诊断市场分析

  • 简介/主要调查结果
  • 市场(金额)分析，2019～2023年
  • 市场(金额)分析与预测，2024～2033年
    • 院内感染
    • 性感染疾病(STD)
    • 败血症
    • 脑膜炎
    • 呼吸系统感染疾病
    • HPV
    • 消化管感染疾病
    • 移植患者的感染疾病
    • B型肝炎和C型肝炎
    • 结核
    • 其他
  • 各应用领域的市场魅力分析

第11章 各终端用户:全球感染疾病诊断市场分析

  • 简介/主要调查结果
  • 市场规模(金额)分析，2019～2023年
  • 市场规模(金额)分析与预测，2024～2033年
    • 医院
    • 诊断检验室
    • 诊所
    • 学术调查机关
    • 其他

各终端用户市场魅力分析

第12章 各地区:全球感染疾病诊断市场分析

  • 简介
  • 市场规模(金额)分析，2019～2023年
  • 市场规模(金额)分析与预测，2024～2033年
    • 北美
    • 南美
    • 欧洲
    • 东亚
    • 南亚
    • 大洋洲
    • 中东及非洲(中东·非洲)
  • 各地区市场的魅力分析

第13章 北美的感染疾病诊断市场分析

第14章 南美的感染疾病诊断市场分析

第15章 欧洲的感染疾病诊断市场分析

第16章 东亚的感染疾病诊断市场分析

第17章 南亚的感染疾病诊断市场分析

第18章 大洋洲的感染疾病诊断市场

第19章 中东·非洲感染疾病诊断市场分析

第20章 市场结构分析

  • 各级企业市场分析
  • 主要企业的市场占有率分析
  • 市场影响分析

第21章 竞争分析

  • 竞争仪表板
  • 竞争基准
  • 竞争详细内容
    • Affymetrix, Inc.
    • Ambion, Inc.
    • Applera Corporation
    • Cenetron Diagnostics
    • Cepheid, Inc.
    • Chiron Corporation
    • Dharmacon, Inc.
    • Digene Corporation
    • Gen-Probe Incorporated
    • Innogenetics NV
    • Nanogen, Inc.
    • F. Hoffmann-La Roche Ltd
    • Becton, Dickinson and Company
    • bioMerieux SA
    • Hologic, Inc.
    • QIAGEN
    • Myriad Genetics, Inc.
    • Thermo Fisher Scientific
    • Meridian Bioscience, Inc.

第22章 所使用的前提条件与缩写

第23章 调查手法

简介目录
Product Code: PMRREP11413

Persistence Market Research has recently published an in-depth report on the global infectious diseases diagnostics market, offering detailed insights into market dynamics, including drivers, trends, opportunities, and challenges. This report aims to provide a comprehensive understanding of the market structure and future outlook, particularly for stakeholders in the healthcare and diagnostics sectors.

Key Insights:

  • Global Market Revenue (2022): US$ 35.1 Billion
  • Estimated Market Value (2033): US$ 55.1 Billion
  • Global Market Growth Rate (CAGR 2022-2033): 4.2%

Global Infectious Diseases Diagnostics Market - Report Scope:

The infectious diseases diagnostics market includes the development, production, and distribution of diagnostic test kits and systems used to identify infectious diseases. The market covers a wide range of diseases, including respiratory infections, sexually transmitted infections (STIs), and other contagious diseases that require timely and accurate diagnosis for effective treatment.

Market Growth Drivers:

Rising Incidence of Infectious Diseases

The global prevalence of infectious diseases continues to rise, driving demand for effective diagnostic solutions. Respiratory diseases and sexually transmitted infections are particularly on the rise, necessitating increased diagnostic testing to manage and control these diseases. For instance, according to World Bank data, 37.7 million people were living with HIV in 2020, with women and girls comprising half of this population. The need for accurate diagnosis and timely treatment of such infections is expected to boost the demand for infectious diseases diagnostics.

Rising Focus on Evidence-Based Medicine (EBM)

Evidence-based medicine (EBM) is gaining importance in the healthcare environment as it helps clinicians achieve higher quality care, improved patient satisfaction, and lower costs. EBM not only involves using evidence to develop treatment protocols but also encourages dialogue between patients and clinicians, allowing patients to participate in decision-making. The emphasis on evidence-based diagnosis is driving the demand for diagnostic kits, as clinicians rely on accurate diagnostic results to guide treatment decisions.

Increasing Demand for Rapid Diagnostic Tests (RDTs)

The demand for rapid diagnostic tests (RDTs) is growing as more patients suffer from infectious diseases that require quick and accurate diagnosis. For example, the World Health Organization (WHO) reported that 3.1 billion RDTs for malaria were sold worldwide between 2010 and 2020, with 81% of these sales going to sub-Saharan African nations. The need for reliable, low-cost diagnostic kits is increasing, presenting significant opportunities for market growth.

Market Challenges:

High Cost of Diagnostic Test Kits

While the market for infectious diseases diagnostics is expanding, the high cost of available diagnostic test kits remains a significant challenge. There is a need for cost-effective test kits with high specificity and sensitivity to make diagnostics more accessible, particularly in low-resource settings. The high cost of current diagnostic tools limits their widespread adoption, especially in developing countries.

Lack of Efficient Diagnostic Test Kits

There is a scarcity of efficient diagnostic test kits for many infectious diseases. The development of affordable and reliable test kits is essential to meet the growing demand for diagnostics in both high-income and low-income regions. Companies are increasingly focusing on research and development to create highly accurate and sensitive diagnostic kits, which is expected to open up new business opportunities in the market.

Opportunities for Growth:

Focus on Infectious Disease Prevention

Different nations are concentrating on preventing infectious diseases to reduce healthcare expenditures. For example, the India Health Fund, in collaboration with the Office of the Principal Scientific Adviser to the Government of India, is calling for innovations to address urgent issues affecting the control, treatment, and cure of infectious diseases. Such initiatives present strong growth opportunities for suppliers of diagnostic kits for infectious diseases, as governments and healthcare organizations seek to enhance their diagnostic capabilities.

Expansion of Research and Development Efforts

The expanding research and development efforts aimed at producing highly accurate and sensitive diagnostic kits are expected to create new business prospects for companies involved in infectious diseases diagnostics. The focus on innovation and the development of more effective diagnostic solutions will likely drive the market's growth in the coming years.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the global infectious diseases diagnostics market?
  • Which consumer segments are leading the adoption of infectious diseases diagnostic solutions?
  • How are technological advancements influencing the competitive landscape?
  • Who are the key players in the global infectious diseases diagnostics market, and what strategies are they employing to maintain their market position?
  • What are the emerging trends and future prospects in the global infectious diseases diagnostics market?

Competitive Intelligence and Business Strategy:

Leading players in the global infectious diseases diagnostics market, such as Abbott Laboratories, Roche Diagnostics, and Thermo Fisher Scientific, are focusing on product innovation, strategic collaborations, and expanding their market presence in emerging economies. These companies are investing heavily in research and development to create advanced diagnostic kits that offer enhanced accuracy and affordability. Collaborations with healthcare providers and governments are enhancing market credibility and driving the adoption of new technologies.

Key Companies Profiled:

  • Affymetrix, Inc.
  • Ambion, Inc.
  • Applera Corporation
  • Cenetron Diagnostics
  • Cepheid, Inc.
  • Chiron Corporation
  • Dharmacon, Inc.
  • Digene Corporation
  • Gen-Probe Incorporated
  • Innogenetics NV
  • Nanogen, Inc.
  • F. Hoffmann-La Roche Ltd
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Hologic, Inc.,
  • QIAGEN
  • Myriad Genetics, Inc.,
  • Thermo Fisher Scientific
  • Meridian Bioscience, Inc.

Key Segments Covered in Infectious Diseases Diagnostics Industry Research

Product:

  • Instrument
  • Kits and reagents
  • consumables

Test Type:

  • Screening Test
  • Diagnostic Test

Application:

  • Hospital- Acquired Infections
  • Sexually Transmitted Disease (STD)
  • Sepsis
  • Meningitis
  • Respiratory Infections
  • HPV
  • Gastrointestinal Tract Infections
  • Infection in Transplant Patients
  • Hepatitis B and C
  • Tuberculosis
  • Others

End User:

  • Hospitals
  • Diagnostic Laboratories
  • Clinics
  • Academic and Research Institutes
  • Others

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Production Adoption Analysis
  • 4.2. Regulatory Scenario
  • 4.3. Reimbursement Landscape
  • 4.4. Supply Chain Analysis
  • 4.5. PESTEL Analysis
  • 4.6. Porter's Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Outlook
    • 5.1.3. Parent Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Development of Novel Products
    • 5.2.2. Regulatory Imposition
    • 5.2.3. Increasing Demand for Rapid Diagnostic Kits
    • 5.2.4. Increasing Production Launches
    • 5.2.5. Growing Government Investment
    • 5.2.6. Strategic Mergers and Acquisitions Among Local
    • 5.2.7. High Demand for PoC Testing
    • 5.2.8. Rising Awareness about Early Testing
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Product
    • 6.1.2. By Test Type
    • 6.1.3. By Application
    • 6.1.4. By End User
    • 6.1.5. By Region
  • 6.2. 2024 Market Scenario

7. Global Infectious Disease Diagnostic Market Demand (in Value US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

  • 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033, By Product

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Bn) Analysis, by Product, 2019-2023
  • 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Product, 2024-2033
  • 8.4. Instrument
    • 8.4.1. Biochips
    • 8.4.2. Microfluidics Based POCT
    • 8.4.3. DNA Microarrays
    • 8.4.4. Mass Spectrometry
    • 8.4.5. Real-time Polymerase Chain Reaction (qPCR)
    • 8.4.6. Fluorescence in situ Hybridization (FISH)
    • 8.4.7. Sequencing
    • 8.4.8. Capillary Electrophoresis
    • 8.4.9. Next Generation Sequencing
  • 8.5. Kits and reagents
    • 8.5.1. Kits
    • 8.5.2. Primary antibodies
    • 8.5.3. Secondary antibodies
    • 8.5.4. Substrates
    • 8.5.5. Buffers
  • 8.6. consumables
  • 8.7. Market Attractiveness Analysis, by Product

9. Global Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033, By Test Type

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Test Type, 2019-2023
  • 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Test Type, 2024-2033
    • 9.3.1. Screening Test
    • 9.3.2. Diagnostic Test
  • 9.4. Market Attractiveness Analysis, by Test Type

10. Global Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033, By Application

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Test Type, 2019-2023
  • 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Application, 2024-2033
    • 10.3.1. Hospital- Acquired Infections
    • 10.3.2. Sexually Transmitted Disease (STD)
    • 10.3.3. Sepsis
    • 10.3.4. Meningitis
    • 10.3.5. Respiratory Infections
    • 10.3.6. HPV
    • 10.3.7. Gastrointestinal Tract Infections
    • 10.3.8. Infection in Transplant Patients
    • 10.3.9. Hepatitis B and C
    • 10.3.10. Tuberculosis
    • 10.3.11. Others
  • 10.4. Market Attractiveness Analysis, by Application

11. Global Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033, By End User

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019-2023
  • 11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by End User, 2024-2033
    • 11.3.1. Hospitals
    • 11.3.2. Diagnostic Laboratories
    • 11.3.3. Clinics
    • 11.3.4. Academic and Research Institutes
    • 11.3.5. Others

Market Attractiveness Analysis, by End User

12. Global Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033, By Region

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Bn) Analysis, by Region, 2019-2023
  • 12.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, By Region, 2024-2033
    • 12.3.1. North America
    • 12.3.2. Latin America
    • 12.3.3. Europe
    • 12.3.4. East Asia
    • 12.3.5. South Asia
    • 12.3.6. Oceania
    • 12.3.7. Middle East and Africa (MEA)
  • 12.4. Market Attractiveness Analysis, by Region

13. North America Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 13.3.1. By Country
      • 13.3.1.1. U.S.
      • 13.3.1.2. Canada
    • 13.3.2. By Product
    • 13.3.3. By Test Type
    • 13.3.4. By Application
    • 13.3.5. By End User
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Product
    • 13.4.3. By Test Type
    • 13.4.4. By Application
    • 13.4.5. By End User
  • 13.5. Market Trends
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. U.S. Infectious Disease Diagnostic Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 13.8.1.2.1. By Product
        • 13.8.1.2.2. By Test Type
        • 13.8.1.2.3. By Application
        • 13.8.1.2.4. By End User
    • 13.8.2. Canada Infectious Disease Diagnostic Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 13.8.2.2.1. By Product
        • 13.8.2.2.2. By Test Type
        • 13.8.2.2.3. By Application
        • 13.8.2.2.4. By End User

14. Latin America Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 14.3.1. By Country
      • 14.3.1.1. Mexico
      • 14.3.1.2. Brazil
      • 14.3.1.3. Argentina
      • 14.3.1.4. Rest of Latin America
    • 14.3.2. By Product
    • 14.3.3. By Test Type
    • 14.3.4. By Application
    • 14.3.5. By End User
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Product
    • 14.4.3. By Test Type
    • 14.4.4. By Application
    • 14.4.5. By End User
  • 14.5. Market Trends
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. Mexico Infectious Disease Diagnostic Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.8.1.2.1. By Product
        • 14.8.1.2.2. By Test Type
        • 14.8.1.2.3. By Application
        • 14.8.1.2.4. By End User
    • 14.8.2. Brazil Infectious Disease Diagnostic Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.8.2.2.1. By Product
        • 14.8.2.2.2. By Test Type
        • 14.8.2.2.3. By Application
        • 14.8.2.2.4. By End User
    • 14.8.3. Argentina Infectious Disease Diagnostic Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.8.3.2.1. By Product
        • 14.8.3.2.2. By Test Type
        • 14.8.3.2.3. By Application
        • 14.8.3.2.4. By End User

15. Europe Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 15.3.1. By Country
      • 15.3.1.1. Germany
      • 15.3.1.2. Italy
      • 15.3.1.3. France
      • 15.3.1.4. U.K.
      • 15.3.1.5. Spain
      • 15.3.1.6. BENELUX
      • 15.3.1.7. Russia
      • 15.3.1.8. Rest of Europe
    • 15.3.2. By Product
    • 15.3.3. By Test Type
    • 15.3.4. By Application
    • 15.3.5. By End User
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Product
    • 15.4.3. By Test Type
    • 15.4.4. By Application
    • 15.4.5. By End User
  • 15.5. Market Trends
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. Germany Infectious Disease Diagnostic Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.1.2.1. By Product
        • 15.8.1.2.2. By Test Type
        • 15.8.1.2.3. By Application
        • 15.8.1.2.4. By End User
    • 15.8.2. Italy Infectious Disease Diagnostic Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.2.2.1. By Product
        • 15.8.2.2.2. By Test Type
        • 15.8.2.2.3. By Application
        • 15.8.2.2.4. By End User
    • 15.8.3. France Infectious Disease Diagnostic Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.3.2.1. By Product
        • 15.8.3.2.2. By Test Type
        • 15.8.3.2.3. By Application
        • 15.8.3.2.4. By End User
    • 15.8.4. U.K. Infectious Disease Diagnostic Market Analysis
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.4.2.1. By Product
        • 15.8.4.2.2. By Test Type
        • 15.8.4.2.3. By Application
        • 15.8.4.2.4. By End User
    • 15.8.5. Spain Infectious Disease Diagnostic Market Analysis
      • 15.8.5.1. Introduction
      • 15.8.5.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.5.2.1. By Product
        • 15.8.5.2.2. By Test Type
        • 15.8.5.2.3. By Application
        • 15.8.5.2.4. By End User
    • 15.8.6. BENELUX Infectious Disease Diagnostic Market Analysis
      • 15.8.6.1. Introduction
      • 15.8.6.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.6.2.1. By Product
        • 15.8.6.2.2. By Test Type
        • 15.8.6.2.3. By Application
        • 15.8.6.2.4. By End User
    • 15.8.7. Russia Infectious Disease Diagnostic Market Analysis
      • 15.8.7.1. Introduction
      • 15.8.7.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.7.2.1. By Product
        • 15.8.7.2.2. By Test Type
        • 15.8.7.2.3. By Application
        • 15.8.7.2.4. By End User

16. East Asia Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033

  • 16.1. Introduction
  • 16.2. Historical Market End User (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 16.3.1. By Country
      • 16.3.1.1. China
      • 16.3.1.2. Japan
      • 16.3.1.3. South Korea
    • 16.3.2. By Product
    • 16.3.3. By Test Type
    • 16.3.4. By Application
    • 16.3.5. By End User
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Product
    • 16.4.2. By Test Type
    • 16.4.3. By Application
    • 16.4.4. By End User
  • 16.5. Market Trends
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. China Infectious Disease Diagnostic Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 16.8.1.2.1. By Product
        • 16.8.1.2.2. By Test Type
        • 16.8.1.2.3. By Application
        • 16.8.1.2.4. By End User
    • 16.8.2. Japan Infectious Disease Diagnostic Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 16.8.2.2.1. By Product
        • 16.8.2.2.2. By Test Type
        • 16.8.2.2.3. By Application
        • 16.8.2.2.4. By End User
    • 16.8.3. South Korea Infectious Disease Diagnostic Market Analysis
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 16.8.3.2.1. By Product
        • 16.8.3.2.2. By Test Type
        • 16.8.3.2.3. By Application
        • 16.8.3.2.4. By End User

17. South Asia Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 17.3.1. By Country
      • 17.3.1.1. India
      • 17.3.1.2. Indonesia
      • 17.3.1.3. Malaysia
      • 17.3.1.4. Thailand
      • 17.3.1.5. Rest of South Asia
    • 17.3.2. By Product
    • 17.3.3. By Test Type
    • 17.3.4. By Application
    • 17.3.5. By End User
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Product
    • 17.4.3. By Test Type
    • 17.4.4. By Application
    • 17.4.5. By End User
  • 17.5. Market Trends
  • 17.6. Key Market Participants - Intensity Mapping
  • 17.7. Drivers and Restraints - Impact Analysis
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. India Infectious Disease Diagnostic Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.8.1.2.1. By Product
        • 17.8.1.2.2. By Test Type
        • 17.8.1.2.3. By Application
        • 17.8.1.2.4. By End User
    • 17.8.2. Indonesia Infectious Disease Diagnostic Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.8.2.2.1. By Product
        • 17.8.2.2.2. By Test Type
        • 17.8.2.2.3. By Application
        • 17.8.2.2.4. By End User
    • 17.8.3. Malaysia Infectious Disease Diagnostic Market Analysis
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.8.3.2.1. By Product
        • 17.8.3.2.2. By Test Type
        • 17.8.3.2.3. By Application
        • 17.8.3.2.4. By End User
    • 17.8.4. Thailand Infectious Disease Diagnostic Market Analysis
      • 17.8.4.1. Introduction
      • 17.8.4.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.8.4.2.1. By Product
        • 17.8.4.2.2. By Test Type
        • 17.8.4.2.3. By Application
        • 17.8.4.2.4. By End User

18. Oceania Infectious Disease Diagnostic Market 2019-2023 and Forecast 2024-2033

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 18.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 18.3.1. By Country
      • 18.3.1.1. Australia
      • 18.3.1.2. New Zealand
    • 18.3.2. By Product
    • 18.3.3. By Test Type
    • 18.3.4. By Application
    • 18.3.5. By End User
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Product
    • 18.4.3. By Test Type
    • 18.4.4. By Application
    • 18.4.5. By End User
  • 18.5. Key Market Participants - Intensity Mapping
  • 18.6. Key Market Participants - Intensity Mapping
  • 18.7. Drivers and Restraints - Impact Analysis
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. Australia Infectious Disease Diagnostic Market Analysis
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 18.8.1.2.1. By Product
        • 18.8.1.2.2. By Test Type
        • 18.8.1.2.3. By Application
        • 18.8.1.2.4. By End User
    • 18.8.2. New Zealand Infectious Disease Diagnostic Market Analysis
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 18.8.2.2.1. By Product
        • 18.8.2.2.2. By Test Type
        • 18.8.2.2.3. By Application
        • 18.8.2.2.4. By End User

19. Middle East and Africa (MEA) Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033

  • 19.1. Introduction
  • 19.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 19.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 19.3.1. By Country
      • 19.3.1.1. GCC Countries
      • 19.3.1.2. Turkiye
      • 19.3.1.3. South Africa
      • 19.3.1.4. North Africa
      • 19.3.1.5. Rest of Middle East and Africa
    • 19.3.2. By Product
    • 19.3.3. By Test Type
    • 19.3.4. By Application
    • 19.3.5. By End User
  • 19.4. Market Attractiveness Analysis
    • 19.4.1. By Product
    • 19.4.2. By Test Type
    • 19.4.3. By Application
    • 19.4.4. By End User
  • 19.5. Market Trends
  • 19.6. Key Market Participants - Intensity Mapping
  • 19.7. Drivers and Restraints - Impact Analysis
  • 19.8. Country Level Analysis & Forecast
    • 19.8.1. GCC Countries Infectious Disease Diagnostic Market Analysis
      • 19.8.1.1. Introduction
      • 19.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 19.8.1.2.1. By Product
        • 19.8.1.2.2. By Test Type
        • 19.8.1.2.3. By Application
        • 19.8.1.2.4. By End User
    • 19.8.2. Turkiye Infectious Disease Diagnostic Market Analysis
      • 19.8.2.1. Introduction
      • 19.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 19.8.2.2.1. By Product
        • 19.8.2.2.2. By Test Type
        • 19.8.2.2.3. By Application
        • 19.8.2.2.4. By End User
    • 19.8.3. South Africa Infectious Disease Diagnostic Market Analysis
      • 19.8.3.1. Introduction
      • 19.8.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 19.8.3.2.1. By Product
        • 19.8.3.2.2. By Test Type
        • 19.8.3.2.3. By Application
        • 19.8.3.2.4. By End User
    • 19.8.4. North Africa Infectious Disease Diagnostic Market Analysis
      • 19.8.4.1. Introduction
      • 19.8.4.2. Market Analysis and Forecast, by Market Taxonomy
        • 19.8.4.2.1. By Product
        • 19.8.4.2.2. By Test Type
        • 19.8.4.2.3. By Application
        • 19.8.4.2.4. By End User

20. Market Structure Analysis

  • 20.1. Market Analysis, by Tier of Companies
  • 20.2. Market Share Analysis of Top Players
  • 20.3. Market Presence Analysis

21. Competition Analysis

  • 21.1. Competition Dashboard
  • 21.2. Competition Benchmarking
  • 21.3. Competition Deep Dive
    • 21.3.1. Affymetrix, Inc.
      • 21.3.1.1. Overview
      • 21.3.1.2. Product Portfolio
      • 21.3.1.3. Sales Footprint
      • 21.3.1.4. Key Financials
      • 21.3.1.5. SWOT Analysis
      • 21.3.1.6. Strategy Overview
        • 21.3.1.6.1. Marketing Strategy
        • 21.3.1.6.2. Product Strategy
        • 21.3.1.6.3. Channel Strategy
    • 21.3.2. Ambion, Inc.
      • 21.3.2.1. Overview
      • 21.3.2.2. Product Portfolio
      • 21.3.2.3. Sales Footprint
      • 21.3.2.4. Key Financials
      • 21.3.2.5. SWOT Analysis
      • 21.3.2.6. Strategy Overview
        • 21.3.2.6.1. Marketing Strategy
        • 21.3.2.6.2. Product Strategy
        • 21.3.2.6.3. Channel Strategy
    • 21.3.3. Applera Corporation
      • 21.3.3.1. Overview
      • 21.3.3.2. Product Portfolio
      • 21.3.3.3. Sales Footprint
      • 21.3.3.4. Key Financials
      • 21.3.3.5. SWOT Analysis
      • 21.3.3.6. Strategy Overview
        • 21.3.3.6.1. Marketing Strategy
        • 21.3.3.6.2. Product Strategy
        • 21.3.3.6.3. Channel Strategy
    • 21.3.4. Cenetron Diagnostics
      • 21.3.4.1. Overview
      • 21.3.4.2. Product Portfolio
      • 21.3.4.3. Sales Footprint
      • 21.3.4.4. Key Financials
      • 21.3.4.5. SWOT Analysis
      • 21.3.4.6. Strategy Overview
        • 21.3.4.6.1. Marketing Strategy
        • 21.3.4.6.2. Product Strategy
        • 21.3.4.6.3. Channel Strategy
    • 21.3.5. Cepheid, Inc.
      • 21.3.5.1. Overview
      • 21.3.5.2. Product Portfolio
      • 21.3.5.3. Sales Footprint
      • 21.3.5.4. Key Financials
      • 21.3.5.5. SWOT Analysis
      • 21.3.5.6. Strategy Overview
        • 21.3.5.6.1. Marketing Strategy
        • 21.3.5.6.2. Product Strategy
        • 21.3.5.6.3. Channel Strategy
    • 21.3.6. Chiron Corporation
      • 21.3.6.1. Overview
      • 21.3.6.2. Product Portfolio
      • 21.3.6.3. Sales Footprint
      • 21.3.6.4. Key Financials
      • 21.3.6.5. SWOT Analysis
      • 21.3.6.6. Strategy Overview
        • 21.3.6.6.1. Marketing Strategy
        • 21.3.6.6.2. Product Strategy
        • 21.3.6.6.3. Channel Strategy
    • 21.3.7. Dharmacon, Inc.
      • 21.3.7.1. Overview
      • 21.3.7.2. Product Portfolio
      • 21.3.7.3. Sales Footprint
      • 21.3.7.4. Key Financials
      • 21.3.7.5. SWOT Analysis
      • 21.3.7.6. Strategy Overview
        • 21.3.7.6.1. Marketing Strategy
        • 21.3.7.6.2. Product Strategy
        • 21.3.7.6.3. Channel Strategy
    • 21.3.8. Digene Corporation
      • 21.3.8.1. Overview
      • 21.3.8.2. Product Portfolio
      • 21.3.8.3. Sales Footprint
      • 21.3.8.4. Key Financials
      • 21.3.8.5. SWOT Analysis
      • 21.3.8.6. Strategy Overview
        • 21.3.8.6.1. Marketing Strategy
        • 21.3.8.6.2. Product Strategy
        • 21.3.8.6.3. Channel Strategy
    • 21.3.9. Gen-Probe Incorporated
      • 21.3.9.1. Overview
      • 21.3.9.2. Product Portfolio
      • 21.3.9.3. Sales Footprint
      • 21.3.9.4. Key Financials
      • 21.3.9.5. SWOT Analysis
      • 21.3.9.6. Strategy Overview
        • 21.3.9.6.1. Marketing Strategy
        • 21.3.9.6.2. Product Strategy
        • 21.3.9.6.3. Channel Strategy
    • 21.3.10. Innogenetics NV
      • 21.3.10.1. Overview
      • 21.3.10.2. Product Portfolio
      • 21.3.10.3. Sales Footprint
      • 21.3.10.4. Key Financials
      • 21.3.10.5. SWOT Analysis
      • 21.3.10.6. Strategy Overview
        • 21.3.10.6.1. Marketing Strategy
        • 21.3.10.6.2. Product Strategy
        • 21.3.10.6.3. Channel Strategy
    • 21.3.11. Nanogen, Inc.
      • 21.3.11.1. Overview
      • 21.3.11.2. Product Portfolio
      • 21.3.11.3. Sales Footprint
      • 21.3.11.4. Key Financials
      • 21.3.11.5. SWOT Analysis
      • 21.3.11.6. Strategy Overview
        • 21.3.11.6.1. Marketing Strategy
        • 21.3.11.6.2. Product Strategy
        • 21.3.11.6.3. Channel Strategy
    • 21.3.12. F. Hoffmann-La Roche Ltd
      • 21.3.12.1. Overview
      • 21.3.12.2. Product Portfolio
      • 21.3.12.3. Sales Footprint
      • 21.3.12.4. Key Financials
      • 21.3.12.5. SWOT Analysis
      • 21.3.12.6. Strategy Overview
        • 21.3.12.6.1. Marketing Strategy
        • 21.3.12.6.2. Product Strategy
        • 21.3.12.6.3. Channel Strategy
    • 21.3.13. Becton, Dickinson and Company
      • 21.3.13.1. Overview
      • 21.3.13.2. Product Portfolio
      • 21.3.13.3. Sales Footprint
      • 21.3.13.4. Key Financials
      • 21.3.13.5. SWOT Analysis
      • 21.3.13.6. Strategy Overview
        • 21.3.13.6.1. Marketing Strategy
        • 21.3.13.6.2. Product Strategy
        • 21.3.13.6.3. Channel Strategy
    • 21.3.14. bioMerieux SA
      • 21.3.14.1. Overview
      • 21.3.14.2. Product Portfolio
      • 21.3.14.3. Sales Footprint
      • 21.3.14.4. Key Financials
      • 21.3.14.5. SWOT Analysis
      • 21.3.14.6. Strategy Overview
        • 21.3.14.6.1. Marketing Strategy
        • 21.3.14.6.2. Product Strategy
        • 21.3.14.6.3. Channel Strategy
    • 21.3.15. Hologic, Inc.
      • 21.3.15.1. Overview
      • 21.3.15.2. Product Portfolio
      • 21.3.15.3. Sales Footprint
      • 21.3.15.4. Key Financials
      • 21.3.15.5. SWOT Analysis
      • 21.3.15.6. Strategy Overview
        • 21.3.15.6.1. Marketing Strategy
        • 21.3.15.6.2. Product Strategy
        • 21.3.15.6.3. Channel Strategy
    • 21.3.16. QIAGEN
      • 21.3.16.1. Overview
      • 21.3.16.2. Product Portfolio
      • 21.3.16.3. Sales Footprint
      • 21.3.16.4. Key Financials
      • 21.3.16.5. SWOT Analysis
      • 21.3.16.6. Strategy Overview
        • 21.3.16.6.1. Marketing Strategy
        • 21.3.16.6.2. Product Strategy
        • 21.3.16.6.3. Channel Strategy
    • 21.3.17. Myriad Genetics, Inc.
      • 21.3.17.1. Overview
      • 21.3.17.2. Product Portfolio
      • 21.3.17.3. Sales Footprint
      • 21.3.17.4. Key Financials
      • 21.3.17.5. SWOT Analysis
      • 21.3.17.6. Strategy Overview
        • 21.3.17.6.1. Marketing Strategy
        • 21.3.17.6.2. Product Strategy
        • 21.3.17.6.3. Channel Strategy
    • 21.3.18. Thermo Fisher Scientific
      • 21.3.18.1. Overview
      • 21.3.18.2. Product Portfolio
      • 21.3.18.3. Sales Footprint
      • 21.3.18.4. Key Financials
      • 21.3.18.5. SWOT Analysis
      • 21.3.18.6. Strategy Overview
        • 21.3.18.6.1. Marketing Strategy
        • 21.3.18.6.2. Product Strategy
        • 21.3.18.6.3. Channel Strategy
    • 21.3.19. Meridian Bioscience, Inc.
      • 21.3.19.1. Overview
      • 21.3.19.2. Product Portfolio
      • 21.3.19.3. Sales Footprint
      • 21.3.19.4. Key Financials
      • 21.3.19.5. SWOT Analysis
      • 21.3.19.6. Strategy Overview
        • 21.3.19.6.1. Marketing Strategy
        • 21.3.19.6.2. Product Strategy
        • 21.3.19.6.3. Channel Strategy

22. Assumptions and Acronyms Used

23. Research Methodology